Literature DB >> 30582337

Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Victor Tseng1,2, Roy L Sutliff1,2, C Michael Hart1,2.   

Abstract

Significance: Peroxisome proliferator-activated receptor-gamma (PPARγ) maintains pulmonary vascular health through coordination of antioxidant defense systems, inflammation, and cellular metabolism. Insufficient PPARγ contributes to pulmonary hypertension (PH) pathogenesis, whereas therapeutic restoration of PPARγ activity attenuates PH in preclinical models. Recent Advances: Numerous studies in the past decade have elucidated the complex mechanisms by which PPARγ in the pulmonary vasculature and right ventricle (RV) protects against PH. The scope of PPARγ-interconnected pathways continues to expand and includes induction of antioxidant genes, transrepression of inflammatory signaling, regulation of mitochondrial biogenesis and bioenergetic integrity, control of cell cycle and proliferation, and regulation of vascular tone through interactions with nitric oxide and endogenous vasoactive molecules. Furthermore, PPARγ interacts with an extensive regulatory network of transcription factors and microRNAs leading to broad impact on cell signaling. Critical Issues: Abundant evidence suggests that targeting PPARγ exerts diverse salutary effects in PH and represents a novel and potentially translatable therapeutic strategy. However, progress has been slowed by an incomplete understanding of how specific PPARγ pathways are critically disrupted across PH disease subtypes and lack of optimal pharmacological ligands. Future Directions: Recent studies indicate that ligand-induced post-translational modifications of the PPARγ receptor differentially induce therapeutic benefits versus adverse side effects of PPARγ receptor activation. Strategies to selectively target PPARγ activity in diseased cells of pulmonary circulation and RV, coupled with development of ligands designed to specifically regulate post-translational PPARγ modifications, may unlock the full therapeutic potential of this versatile master transcriptional and metabolic regulator in PH.

Entities:  

Keywords:  PPARγ; antioxidants; hypoxia; oxidative stress; pulmonary hypertension; thiazolidinedione

Year:  2019        PMID: 30582337      PMCID: PMC6751396          DOI: 10.1089/ars.2018.7695

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  197 in total

1.  Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.

Authors:  K Subbaramaiah; D T Lin; J C Hart; A J Dannenberg
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

2.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

Authors:  V Pasceri; H D Wu; J T Willerson; E T Yeh
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

3.  Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.

Authors:  Masayuki Asakawa; Hiroyuki Takano; Toshio Nagai; Hiroki Uozumi; Hiroshi Hasegawa; Naoto Kubota; Toshihiro Saito; Yoshiaki Masuda; Takashi Kadowaki; Issei Komuro
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

4.  Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid.

Authors:  H Y Yoo; M S Chang; H M Rho
Journal:  Gene       Date:  1999-06-24       Impact factor: 3.688

5.  Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.

Authors:  M Li; G Pascual; C K Glass
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

6.  Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter.

Authors:  Geoffrey D Girnun; Frederick E Domann; Steven A Moore; Mike E C Robbins
Journal:  Mol Endocrinol       Date:  2002-12

7.  Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction.

Authors:  S M Jackson; F Parhami; X P Xi; J A Berliner; W A Hsueh; R E Law; L L Demer
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

8.  Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes.

Authors:  K Yamamoto; R Ohki; R T Lee; U Ikeda; K Shimada
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

9.  Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth.

Authors:  Shingo Ameshima; Heiko Golpon; Carlyne D Cool; Daniel Chan; R William Vandivier; Shyra J Gardai; Marilee Wick; Raphael A Nemenoff; Mark W Geraci; Norbert F Voelkel
Journal:  Circ Res       Date:  2003-04-24       Impact factor: 17.367

10.  Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells.

Authors:  David S Calnek; Louis Mazzella; Susanne Roser; Jesse Roman; C Michael Hart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

View more
  9 in total

1.  Compartmentalization of Redox-Regulated Signaling in the Pulmonary Circulation.

Authors:  Stephen M Black; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-07-03       Impact factor: 8.401

Review 2.  Vascular Metabolic Mechanisms of Pulmonary Hypertension.

Authors:  Xiao-Fan Shi; Yun-Chao Su
Journal:  Curr Med Sci       Date:  2020-07-17

3.  PPARγ increases HUWE1 to attenuate NF-κB/p65 and sickle cell disease with pulmonary hypertension.

Authors:  Andrew J Jang; Sarah S Chang; Changwon Park; Choon-Myung Lee; Raymond L Benza; Michael J Passineau; Jing Ma; David R Archer; Roy L Sutliff; C Michael Hart; Bum-Yong Kang
Journal:  Blood Adv       Date:  2021-01-26

4.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

Review 5.  Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry.

Authors:  Xiran Lin; Xianmin Meng; Zhiqi Song; Jingrong Lin
Journal:  Mol Cell Biochem       Date:  2022-03-29       Impact factor: 3.396

6.  Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.

Authors:  Di Chen; Hui-Fang Zhang; Tian-Yi Yuan; Shu-Chan Sun; Ran-Ran Wang; Shou-Bao Wang; Lian-Hua Fang; Yang Lyu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

7.  Sildenafil protects against pulmonary hypertension induced by hypoxia in neonatal rats via activation of PPARγ‑mediated downregulation of TRPC.

Authors:  Wanjie Huang; Na Liu; Xin Tong; Yanna Du
Journal:  Int J Mol Med       Date:  2021-12-22       Impact factor: 4.101

8.  FGF21 attenuates pulmonary arterial hypertension via downregulation of miR-130, which targets PPARγ.

Authors:  Meibin Wang; Lihuang Su; Junwei Sun; Luqiong Cai; Xiuchun Li; Xiayan Zhu; Lanlan Song; Jingyin Li; Shuolan Tong; Qinlian He; Mengsi Cai; Lehe Yang; Yanfan Chen; Liangxing Wang; Xiaoying Huang
Journal:  J Cell Mol Med       Date:  2022-01-06       Impact factor: 5.295

9.  PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation.

Authors:  Shuang Nie; Zhao Shi; Mengyue Shi; Hongzhen Li; Xuetian Qian; Chunyan Peng; Xiwei Ding; Shu Zhang; Ying Lv; Lei Wang; Bo Kong; Xiaoping Zou; Shanshan Shen
Journal:  Front Cell Dev Biol       Date:  2022-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.